NCT01746238 2025-12-19
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Massachusetts General Hospital
Phase 1 Active not recruiting
Clinical Trials
23 trialsNCT07027423 2025-12-01
BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Not yet recruiting
NCT02811523 2025-11-26
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
University Health Network, Toronto
Phase 1 Recruiting
NCT05858710 2025-07-28
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Thermosome GmbH
Phase 1 Completed
NCT05100628 2025-01-06
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Noxopharm Limited
Phase 1 Terminated
NCT04032964 2024-04-08
DOXO75
Philogen S.p.A.
Phase 1 Active not recruiting
NCT03009201 2023-08-16
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02076620 2022-04-04
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Philogen S.p.A.
Phase 1 Completed
NCT03042819 2021-12-09
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Completed
NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02326025 2019-11-21
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT01375699 2019-08-26
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Virginia Commonwealth University
Phase 1 Completed
NCT03002805 2019-08-19
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
CBA Research
Phase 1 Unknown
NCT02783599 2019-08-12
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01605526 2016-11-02
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Hoffmann-La Roche
Phase 1 Completed
NCT00720174 2016-05-17
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00288431 2015-07-22
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00742924 2014-07-04
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Children's Oncology Group
Phase 1 Completed
NCT00098579 2013-03-19
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00102609 2013-01-10
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Completed
NCT00004109 2012-08-02
Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00004123 2012-07-30
Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma
M.D. Anderson Cancer Center
Phase 1 Completed